Therapeutic Transformation for Patients with Diabetes and CKDRPA Annual Meeting
SGLT2 inhibitors represent a major advance in the treatment of patients with chronic kidney disease due to their ability to slow progression of CKD and delay the need for dialysis. They also have been shown to have cardio-protective effects.
Clinical InstituteKidney & Diabetes
Citation InformationKatherine Tuttle. "Therapeutic Transformation for Patients with Diabetes and CKD" RPA Annual Meeting (2021)
Available at: http://works.bepress.com/katherine-tuttle/367/